| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1030428417 |
| P356 | DOI | 10.1038/SJ.GT.3302766 |
| P698 | PubMed publication ID | 16688207 |
| P5875 | ResearchGate publication ID | 7093532 |
| P2093 | author name string | Danos O | |
| Rivière C | |||
| Douar AM | |||
| P2860 | cites work | Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors | Q45873434 |
| Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors | Q45879602 | ||
| Major role of local immune responses in antibody formation to factor IX in AAV gene transfer | Q45883516 | ||
| Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors | Q45886179 | ||
| The efficient expression of intravascularly delivered DNA in rat muscle | Q45887040 | ||
| Discrimination between different types of human adeno-associated viruses in clinical samples by PCR | Q74653195 | ||
| Femoral intra-arterial injection: a tool to deliver and assess recombinant AAV constructs in rodents whole hind limb | Q81364860 | ||
| Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy | Q24535690 | ||
| Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers | Q33782809 | ||
| Full functional rescue of a complete muscle (TA) in dystrophic hamsters by adeno-associated virus vector-directed gene therapy | Q33793572 | ||
| CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors in vivo: role of immature dendritic cells | Q33810726 | ||
| Immune responses to adenovirus and adeno-associated virus in humans. | Q33874473 | ||
| AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. | Q34168942 | ||
| Clades of Adeno-associated viruses are widely disseminated in human tissues. | Q34193756 | ||
| Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein | Q34371678 | ||
| Adeno-associated viruses undergo substantial evolution in primates during natural infections | Q35022838 | ||
| Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector | Q35872651 | ||
| Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein | Q35943644 | ||
| Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. | Q36438711 | ||
| Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure | Q39589248 | ||
| Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle | Q39589663 | ||
| Intracellular trafficking of adeno-associated virus vectors: routing to the late endosomal compartment and proteasome degradation | Q39602167 | ||
| Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer | Q39603323 | ||
| Characterization of tissue tropism determinants of adeno-associated virus type 1. | Q39700318 | ||
| Role for highly regulated rep gene expression in adeno-associated virus vector production | Q39880225 | ||
| Myocardial gene transfer and long-term expression following intracoronary delivery of adeno-associated virus | Q40498312 | ||
| Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3. | Q41190212 | ||
| Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. | Q41722852 | ||
| Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. | Q43727676 | ||
| Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector | Q43783192 | ||
| Immune responses to recombinant adeno-associated virus vectors: putting preclinical findings into perspective | Q44235610 | ||
| Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX. | Q44937538 | ||
| Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy | Q44976981 | ||
| Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart | Q45507049 | ||
| Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6. | Q45571369 | ||
| Immunity to adeno-associated virus serotype 2 delivered transgenes imparted by genetic predisposition to autoimmunity | Q45698037 | ||
| Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors | Q45732679 | ||
| Factors influencing cross-presentation of non-self antigens expressed from recombinant adeno-associated virus vectors | Q45736630 | ||
| Route of administration determines induction of T-cell-independent humoral responses to adeno-associated virus vectors. | Q45741128 | ||
| Improved adeno-associated virus vector production with transfection of a single helper adenovirus gene, E4orf6. | Q45741130 | ||
| Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). | Q45747007 | ||
| Recombinant adeno-associated virus for muscle directed gene therapy | Q45764433 | ||
| Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration | Q45862335 | ||
| Erythropoietin gene therapy leads to autoimmune anemia in macaques | Q45871284 | ||
| Autoimmune anemia in macaques following erythropoietin gene therapy | Q45871935 | ||
| P433 | issue | 17 | |
| P304 | page(s) | 1300-1308 | |
| P577 | publication date | 2006-05-11 | |
| P1433 | published in | Gene Therapy | Q15763095 |
| P1476 | title | Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice | |
| P478 | volume | 13 |
| Q35568505 | A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. |
| Q33432320 | A comparison of synthetic oligodeoxynucleotides, DNA fragments and AAV-1 for targeted episomal and chromosomal gene repair |
| Q34814931 | A dystrophic muscle broadens the contribution and activation of immune cells reacting to rAAV gene transfer |
| Q33659389 | AAV's anatomy: roadmap for optimizing vectors for translational success |
| Q40334450 | AAV-mediated delivery of optogenetic constructs to the macaque brain triggers humoral immune responses |
| Q36708300 | AAV-mediated gene transfer for retinal diseases |
| Q35204876 | AAV-mediated in vivo knockdown of luciferase using combinatorial RNAi and U1i. |
| Q41655580 | AAVrh.10 immunogenicity in mice and humans. Relevance of antibody cross-reactivity in human gene therapy. |
| Q33601446 | Actin scaffolding by clathrin heavy chain is required for skeletal muscle sarcomere organization |
| Q35080025 | Adeno-associated viral vector serotype 5 poorly transduces liver in rat models |
| Q30885494 | Adeno-associated viral vectors and their redirection to cell-type specific receptors |
| Q34656049 | Advances in gene therapy for movement disorders. |
| Q47778748 | Allele-specific silencing therapy for Dynamin 2-related dominant centronuclear myopathy |
| Q37412239 | Biological gene delivery vehicles: beyond viral vectors |
| Q37581545 | Cell based therapy for Duchenne muscular dystrophy |
| Q33713259 | Comparative study of anti-hepatitis B virus RNA interference by double-stranded adeno-associated virus serotypes 7, 8, and 9. |
| Q39044467 | Comparison of Serum rAAV Serotype-Specific Antibodies in Patients with Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Inclusion Body Myositis, or GNE Myopathy |
| Q33832790 | Comparison of adeno-associated virus pseudotype 1, 2, and 8 vectors administered by intramuscular injection in the treatment of murine phenylketonuria |
| Q30493438 | DHPR alpha1S subunit controls skeletal muscle mass and morphogenesis. |
| Q33296224 | Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer |
| Q38069585 | Development of Novel Recombinant AAV Vectors and Strategies for the Potential Gene Therapy of Hemophilia |
| Q30152887 | Development of Patient-specific AAV Vectors After Neutralizing Antibody Selection for Enhanced Muscle Gene Transfer |
| Q39015003 | Dysferlin rescue by spliceosome-mediated pre-mRNA trans-splicing targeting introns harbouring weakly defined 3' splice sites |
| Q37226783 | Effect of vascular endothelial growth factor gene therapy on post-traumatic peripheral nerve regeneration and denervation-related muscle atrophy |
| Q45872187 | Effect of viral dose on neutralizing antibody response and transgene expression after AAV1 vector re-administration in mice |
| Q59360867 | Efficient Delivery of Human Cytomegalovirus T Cell Antigens by Attenuated Sendai Virus Vectors |
| Q39998139 | Efficient gene transfer in skeletal muscle with AAV-derived bicistronic vector using the FGF-1 IRES. |
| Q92635178 | Emerging Concepts and Challenges in Rheumatoid Arthritis Gene Therapy |
| Q33728191 | Establishment of an AAV Reverse Infection-Based Array |
| Q40274940 | Ex vivo serotype-specific transduction of equine joint tissue by self-complementary adeno-associated viral vectors |
| Q33713881 | Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of Alzheimer disease |
| Q40212331 | Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies |
| Q34180144 | Gene Therapy for Muscular Dystrophies: Progress and Challenges |
| Q34566454 | Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors |
| Q91972798 | Gene therapy for progressive familial intrahepatic cholestasis type 3 in a clinically relevant mouse model |
| Q38016275 | Gene therapy for the treatment of chronic peripheral nervous system pain |
| Q81897639 | Growth inhibition of an established A431 xenograft tumor by a full-length anti-EGFR antibody following gene delivery by AAV |
| Q39465145 | High-Density Recombinant Adeno-Associated Viral Particles are Competent Vectors for In Vivo Transduction |
| Q39890263 | Highly efficient transduction of human plasmacytoid dendritic cells without phenotypic and functional maturation. |
| Q35513407 | Immune Responses to rAAV6: The Influence of Canine Parvovirus Vaccination and Neonatal Administration of Viral Vector |
| Q37127246 | Immunity to adeno-associated virus vectors in animals and humans: a continued challenge |
| Q90000829 | Immunoadsorption enables successful rAAV5-mediated repeated hepatic gene delivery in nonhuman primates |
| Q34237002 | Impaired adaptive response to mechanical overloading in dystrophic skeletal muscle |
| Q36315561 | Lack of repeat transduction by recombinant adeno-associated virus type 5/5 vectors in the mouse airway |
| Q46666393 | Long-Term PEDF Release in Rat Iris and Retinal Epithelial Cells after Sleeping Beauty Transposon-Mediated Gene Delivery. |
| Q45869991 | Long-term VEGF-A expression promotes aberrant angiogenesis and fibrosis in skeletal muscle |
| Q45361267 | Long-term functional adeno-associated virus-microdystrophin expression in the dystrophic CXMDj dog. |
| Q37601170 | Long-term transduction of miniature pig parotid glands using serotype 2 adeno-associated viral vectors |
| Q40168483 | Major subsets of human dendritic cells are efficiently transduced by self-complementary adeno-associated virus vectors 1 and 2. |
| Q40055959 | Muscle Gene Therapy for Hemophilia. |
| Q36142477 | MyD88 signaling in B cells regulates the production of Th1-dependent antibodies to AAV |
| Q42217395 | Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors |
| Q36174173 | New vectors and strategies for cardiovascular gene therapy |
| Q42204796 | Pancreatic transduction by helper-dependent adenoviral vectors via intraductal delivery. |
| Q27013613 | Perspectives of stem cell therapy in Duchenne muscular dystrophy |
| Q27324340 | Predictors of hepatitis B cure using gene therapy to deliver DNA cleavage enzymes: a mathematical modeling approach |
| Q37011150 | Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection. |
| Q36469478 | Proinsulin slows retinal degeneration and vision loss in the P23H rat model of retinitis pigmentosa |
| Q40063676 | Prolonged susceptibility to antibody-mediated neutralization for adeno-associated vectors targeted to the liver |
| Q37621530 | Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies |
| Q41876346 | Promoterless gene targeting without nucleases rescues lethality of a Crigler-Najjar syndrome mouse model |
| Q30519561 | Protein-anchoring strategy for delivering acetylcholinesterase to the neuromuscular junction |
| Q28386583 | Recombinant adeno-associated viral (rAAV) vectors mediate efficient gene transduction in cultured neonatal and adult microglia |
| Q37325074 | Reprogramming the Dynamin 2 mRNA by Spliceosome-mediated RNA Trans-splicing |
| Q36757156 | Robust Long-term Transduction of Common Marmoset Neuromuscular Tissue With rAAV1 and rAAV9. |
| Q54457954 | Safety and Efficacy of Regional Intravenous (RI) Versus Intramuscular (IM) Delivery of rAAV1 and rAAV8 to Nonhuman Primate Skeletal Muscle. |
| Q38168940 | Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera®). |
| Q36756695 | Serotype-specific Binding Properties and Nanoparticle Characteristics Contribute to the Immunogenicity of rAAV1 Vectors |
| Q36171820 | Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles |
| Q35511648 | Specific binding of collagen Q to the neuromuscular junction is exploited to cure congenital myasthenia and to explore bases of myasthenia gravis |
| Q33739804 | Subretinal delivery of adeno-associated virus serotype 2 results in minimal immune responses that allow repeat vector administration in immunocompetent mice. |
| Q40166892 | Successful Repeated Hepatic Gene Delivery in Mice and Non-human Primates Achieved by Sequential Administration of AAV5ch and AAV1. |
| Q93190169 | Temporary Reduction of Membrane CD4 with the Antioxidant MnTBAP Is Sufficient to Prevent Immune Responses Induced by Gene Transfer |
| Q39126011 | The prevalence of neutralizing antibodies against AAV serotype 1 in healthy subjects in China: implications for gene therapy and vaccines using AAV1 vector |
| Q36549699 | Therapeutic restoration of dystrophin expression in Duchenne muscular dystrophy. |
| Q34233343 | Transduction of the inner mouse retina using AAVrh8 and AAVrh10 via intravitreal injection |
| Q40144395 | Transgene persistence and cell turnover in the diarthrodial joint: implications for gene therapy of chronic joint diseases |
| Q53775896 | Transient immunomodulation allows repeated injections of AAV1 and correction of muscular dystrophy in multiple muscles. |
| Q34127579 | Translating Sleeping Beauty transposition into cellular therapies: victories and challenges |
| Q92649142 | Viral-Mediated Optogenetic Stimulation of Peripheral Motor Nerves in Non-human Primates |
| Q36690402 | Viral-mediated expression of desmin mutants to create mouse models of myofibrillar myopathy |
| Q40168295 | X-chromosome linked inhibitor of apoptosis protein inhibits muscle proteolysis in insulin-deficient mice |
Search more.